Inhibitex, Inc. (NASDAQ: INHX) is a biopharmaceutical company engaging in the development of differentiated anti-infective products designed to prevent and treat serious infections. The company’s products include FV-100, a nucleoside analogue prodrug; HIV Integrase Inhibitors class of anti-retroviral agents; and a series of nucleoside and non-nucleoside HCV polymerase inhibitors designed to treat the hepatitis C virus. For further information, visit the Company’s web site at www.inhibitex.com.
- 18 years ago
QualityStocks
Inhibitex, Inc. (NASDAQ: INHX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…